Saúde Pública/Medicina Humanitária

#COVID19 quarantine period may be shortened for contacts who test negative on a PCR or antigen based rapid diagnostic test. Quarantine can be shortened, for example to seven days, if the contact shows no symptoms & presents a negative test https://t.co/ERF0HDcJOU https://t.co/TsbcHw86B7

— World Health Organization (WHO) (@WHO) February 17, 2022

Opinião | Os coronavírus são “espertos”: cenários evolutivos para o futuro do SARS-CoV-2.

19 Fev, 2022 | 14:01h

Coronaviruses are ‘clever’: Evolutionary scenarios for the future of SARS-CoV-2 – STAT

Perspectiva | Estamos entrando na fase de controle da pandemia.

19 Fev, 2022 | 13:59h

We’re Entering the Control Phase of the Pandemic – The Atlantic

Estimativas de prevalência global, regional e nacional da violência conjugal física ou sexual, ou ambas, contra mulheres.

19 Fev, 2022 | 13:57h

Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018 – The Lancet

Comunicado de imprensa: More than a quarter of women have experienced intimate partner violence in their lifetimes, finds new study – The Lancet

Comentário: Intimate partner violence against women: a persistent and urgent challenge – The Lancet

Comentário no Twitter (fio – clique para saber mais)

NEW—Over 1 in 4 women have experienced intimate partner violence in their lifetimes, study finds.

Authors highlight urgent need to strengthen the public health response in post-COVID-19 reconstruction efforts. https://t.co/yZ61fqIZlV pic.twitter.com/AeMSicRUY0

— The Lancet (@TheLancet) February 17, 2022

Bioterrorismo: uma análise dos agentes biológicos usados em ataques terroristas.

19 Fev, 2022 | 13:44h

Bioterrorism: An analysis of biological agents used in terrorist events – The American Journal of Emergency Medicine

Dengue: importância global, imunopatologia e tratamento.

19 Fev, 2022 | 13:28h

Dengue infection: Global importance, immunopathology and management – Clinical Medicine Journal

Estudo randomizado | Nirmatrelvir oral para adultos de alto risco com Covid-19 reduz em 89% o risco de internação.

17 Fev, 2022 | 15:37h

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Entrevista em áudio: A New Antiviral against Covid-19 – new England Journal of Medicine

Conteúdos relacionados:

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

Comentário no Twitter

The Paxlovid pill (Nirmatrelvir) randomized, placebo-controlled trial published @NEJM:
89% efficacy vs Covid hospitalizations or deaths, and quick reduction of viral load.
The active pills had less serious adverse events or discontinuations than placebohttps://t.co/HBMRZt4wBo pic.twitter.com/LDQv41O56c

— Eric Topol (@EricTopol) February 16, 2022

Liberado pelo Advisory Committee on Immunization Practices (ACIP) o novo calendário de imunização de crianças e adolescentes nos EUA.

Estudo de coorte | Riscos de desfechos de saúde mental em pessoas com Covid-19.

Outro estudo sugere que há um risco menor de internação e morte na infecção pela variante Ômicron do SARS-CoV-2 vs. a variante Delta.

Diretriz provisória da OMS | Rastreamento de contatos e quarentena no contexto da variante Ômicron do SARS-CoV-2.